A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 26 May 2016 Status changed from active, no longer recruiting to completed, as per results published in the British Journal of Haematology.
- 04 Feb 2013 Planned end date changed from 1 Jan 2011 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 17 Jun 2011 Planned end date changed from 1 Apr 2008 to 1 Jan 2011 as reported by ClinicalTrials.gov.